# Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD

> **NCT01128179** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 35 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Lanthanum carbonate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01128179
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-06
- **Primary completion:** 2012-04-16
- **Final completion:** 2012-04-16
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128179, "Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01128179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*